Publications View
BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics.
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.
Authors: Authors: Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ.
Cancer Cell
View full abstract on Pubmed
Cancer Cell
View full abstract on Pubmed
Cancer, coagulation, and anticoagulation.
The importance of intramolecular ion pairing in intermediate filaments.
Genetic bases of epidermolysis bullosa simplex and epidermolytic hyperkeratosis.
Authors: Authors: Fuchs E, Coulombe P, Cheng J, Chan YM, Hutton E, Syder A, Degenstein L, Yu QC, Letai A, Vassar R.
J Invest Dermatol
View full abstract on Pubmed
J Invest Dermatol
View full abstract on Pubmed
Disease severity correlates with position of keratin point mutations in patients with epidermolysis bullosa simplex.
Authors: Authors: Letai A, Coulombe PA, McCormick MB, Yu QC, Hutton E, Fuchs E.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Proc Natl Acad Sci U S A
View full abstract on Pubmed
The genetic basis of epidermolytic hyperkeratosis: a disorder of differentiation-specific epidermal keratin genes.
Authors: Authors: Cheng J, Syder AJ, Yu QC, Letai A, Paller AS, Fuchs E.
Cell
View full abstract on Pubmed
Cell
View full abstract on Pubmed
Do the ends justify the mean? Proline mutations at the ends of the keratin coiled-coil rod segment are more disruptive than internal mutations.
Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: genetic and functional analyses.
Authors: Authors: Coulombe PA, Hutton ME, Letai A, Hebert A, Paller AS, Fuchs E.
Cell
View full abstract on Pubmed
Cell
View full abstract on Pubmed
Pancreas-graft immunogenicity and pretreatment with anti-class II monoclonal antibodies.
Authors: Authors: Lloyd DM, Cotler SJ, Letai AG, Stuart FP, Thistlethwaite JR.
Diabetes
View full abstract on Pubmed
Diabetes
View full abstract on Pubmed